Your recent article panning methyl-tertbutyl ether use (EHP 102:913) was extremely misleading and focused on unpublished, and therefore not critically reviewed data, which is inconsistent with standards of scientific journals. Given the confusion caused by the article, you should provide more accurate information to your readers on why methyl-tert-butyl ether (MTBE) is in gasoline and how it is being managed in a manner protective of public health.
In 1990, Congress passed the Clean Air Act Amendments, which contained a requirement to include oxygen in fuel to reduce carbon monoxide (CO) emissions from motor vehicles. Once oxygenates were required by law, the industry began the process of tooling up for the production of oxygenated fuels. Either alcohols or ethers can be added to provide oxygen and both have been used previously. During the 1979 fuel crisis, alcohols had been added to gasoline to form gasohol. MTBE was added to gasoline as an octane enhancer after the lead phase-out. MTBE had also been used in a three-year pilot CO reduction program in the Southwest beginning in the winter of [1989] [1990] .
There was a considerable body of toxicological data on MTBE, including neu Increased interstitial cell adenoma tumor incidence observed in the testes of male rats in the inhalation study mentioned above was considered to contribute to the weight of evidence of carcinogenicity. A significant dose response in tumor incidence was seen from 64% in concurrent controls to 94% among the highdose rats. The historical incidence of testicular adenomas in these rats ranges from 86 to 91%, but concurrent controls are generally considered the most appropriate controls for comparison. The high spontaneous background rate of testicular tumors in this strain of rat makes interpretation of the significance of the data difficult, but the clear dose-response effect compels the SAB to include these benign tumors in the weight of evidence of carcinogenicity.
Female CD-1 mice exposed to 8,000 ppm MTBE exhibited a significant increase in liver adenoma tumor incidence, which was considered part of the weight of evidence for carcinogenicity. No increase in tumor incidence was observed at the lower two doses. Body weight gain in mice exposed to 8,000 ppm was decreased 24% compared to controls, which may indicate the maximum tolerated dose was exceeded.
Male mice exposed to 8,000 ppm MTBE exhibited an increase in liver carcinoma incidence, which was considered part of the weight of evidence for carcinogenicity. Body weight gain in male mice exposed to 8,000 ppm was reduced by 15%, and the mortality rate of males was increased at this dose. These factors indicate the 8,000 ppm exposure may have exceeded the maximum tolerated dose in male mice. A chronic study in which MTBE was administered to Sprague-Dawley rats by gavage in an olive oil vehicle reportedly has been conducted in Italy by Maltoni. A representative of Maltoni's laboratory, Dr. Myton Mehlman, reported "dose-related" increases in combined lymphoma and leukemias, hematoreticular tumors, uterine sarcomas, and testicular Leydig cell tumors in MTBE-treated rats. The experimental design and results of this study have not been sufficiently reported or reviewed to allow the information to be used in a weight-of-the-evidence evaluation of carcinogenicity.
The SAB concludes there is "some evidence" for carcinogenicity of MTBE in animals according to NTP guidelines for peer-reviewed data characterizing carcinogenic activity of chemicals. The board recognizes "some evidence" in the NTP classification system approximately corresponds to a "C" carcinogen in the EPA classification system. The board's policy as recommended in 1986 by the North Carolina Academy of Sciences is not to assess carcinogenicity risks for compounds the EPA has designated group C carcinogens. The SAB was asked specifically to review carcinogenicity of MTBE because its use as an oxygenate in gasoline could result in exposure of a large number of people to MTBE. In an exception to the policy of not quantifying risk for group C carcinogens, the board estimated a range of exposure levels that could be as high as 10-5 risk.
Assuming MTBE is a carcinogen in humans, the data from animal studies were used by the SAB to calculate an estimate of human risk due to exposure. The calculations were based on the kidney tumor incidence in male rats chronically exposed to Conclusion. The SAB determined there is some evidence for carcinogenicity of MTBE in animals. The SAB estimated a human risk of cancer due to MTBE exposure by extrapolating from the animal data to estimate a risk to humans. The risk calculations were used to estimate concentrations of MTBE which would pose minimal risk to humans exposed continuously for 70 years. The range of concentrations calculated by the SAB expected to pose a 10-5 risk was 0.04 mg/m3 to 0.64 mg/m3. The EPA estimated that an adult commuter who lives next to a gas station could be exposed to 0.03 to 0.05 mg/m3 of MTBE annually in a locale which has a four-month oxyfuel season. The SAB and EPA estimations indicate that the range of potential risk of maximally exposed people in North Carolina may be between 1 x 10-5 and zero at current exposure levels.
